95PD - Molecular heterogeneity and response to gefitinib of EGFR mutant advanced lung adenocarcinoma

Date 27 March 2014
Event ELCC 2014
Session Poster Discussion 1
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Personalised Medicine
Presenter Emilio Bria
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors E. Bria1, S. Pilotto1, E. Amato2, M. Fassan2, S. Novello3, T. Vavalà3, L. Righi3, I. Sperduti4, A. Scarpa5, G. Tortora1
  • 1Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Roma", 37134 - Verona/IT
  • 2Applied Research On Cancer Center, ARC-NET, 37134 - Verona/IT
  • 3Medical Oncology, Azienda Ospedaliero-Universitaria ASOU San Luigi Gonzaga, Orbassano, Turin/IT
  • 4Biostatistics, Regina Elena National Cancer Institute, 00144 - Roma/IT
  • 5Pathology And Diagnostics, University of Verona, 37134 - Verona/IT


Among EGFR mutant advanced lung adenocarcinoma (ALA) patients treated with Gefitinib, 40% benefit for >12 months, while 1/3 rapidly progress. Assessment of molecular heterogeneity may help identify these clinically relevant subgroups.